Table I.

Demographics of the primary panel used for in vitro testing as part of the PPTP.

Cell Line	Diagnosis		Treatment	Site of specimen	Age at Dx	Gender	Ref.
	Rhabdomyosarcoma
RD	Embryonal		Post-Tx*	muscle	7	F	[9]
Rh41	Alveolar		Post-Tx	lung		F	[10]
Rh18	Embryonal		DX§	perineum	2		[11]
Rh30	Alveolar		DX	bone marrow	16	M	[12]
	Brain tumor
BT-12	Atypical teratoid/rhabdoid		DX				[13]
SJ-GBM2	Glioblastoma multiforme		Post-Tx	brain	5	F	[14]
CHLA-266	Atypical teratoid/rhabdoid		DX	posterior fossa	1.5	F	[15]
	Ewings Family of Tumors (EFT)
CHLA-9	PNET		DX	thorax	14	F	[3]
CHLA-10	PNET		Post-Tx	thorax	14	F	[3]
CHLA-258	PNET		Post-BMT**	lung	12	F	[3]
TC-71	Ewings		Post-Tx	bone marrow	22	M	[16]
	Neuroblastoma	MYCN status†
NB-1643	Neuroblastoma	A	DX	adrenal mass	<3		[17]
NB-EBc1	Neuroblastoma	NA	Post-Tx	retroperitoneal mass	<3		[17]
CHLA-90	Neuroblastoma	NA	Post-BMT	bone marrow	8	M	[18]
CHLA-136	Neuroblastoma	A	Post-BMT	blood	3	F	[19]
	Leukemia
NALM-6	Pre-B cell ALL		Post-Tx*	peripheral blood	19	M	[20]
RS4;11	Pre-B cell ALL		Post-Tx	bone marrow	32	F	[21]
COG-LL-317	T-cell ALL		Post-Tx	bone marrow	1.7	M	[22]
MOLT-4	T-cell ALL		Post-Tx	peripheral blood	19	M	[23]
CCRF-CEM	T-cell ALL		Post-Tx	peripheral blood	4	F	[24]
Kasumi-1	AML		Post-BMT**	peripheral blood	7	M	[25]
	Lymphoma
Karpas-299	Anaplastic Large Cell		Post-Tx	peripheral blood	25	M	[26]
Ramos-RA1	Burkitt			peripheral blood	3	M	[27, 28]

^*Cell line established from patients at relapse following chemotherapy;

^**Cell line established from patients at relapse following myeloablative chemotherapy supported by bone marrow transplantation;

^§Cell line established from patient at diagnosis prior to treatment;

^†Genomic amplification of MYCN; A: amplified, NA: not amplified